Zydus Lifesciences Achieves ₹79.1 Billion Revenue in Q2 FY27 with 29% YoY Growth and Expands Specialty Pharmaceutical Portfolio
Strong double-digit growth across India, international markets and North America segments supports 24% EBITDA margin amid US Saroglitazar launch investments
Zydus Lifesciences posted consolidated revenues of ₹79.1 billion for Q2 FY27, marking a 29% year-on-year increase. The company maintained a robust EBITDA margin of 24% despite ongoing investments in the US Saroglitazar launch, with net profit reaching ₹9.3 billion. Key segments such as India branded formulations, international markets, North American generics and specialty businesses, and consumer wellness showed strong double-digit growth during the quarter.
Zydus Lifesciences Limited
Earnings Call Transcript
Zydus Lifesciences reported consolidated revenues of ₹79.1 billion for the second quarter ended September 30, 2026, representing a 29% year-on-year increase. The company recorded an EBITDA margin of 24% despite ongoing investment in Saroglitazar launch activities in the United States, with net profit at ₹9.3 billion.
The India branded formulations business grew 19% year-on-year, outperforming the Indian pharmaceutical market with a 20% increase in secondary sales mainly driven by volume and new product launches. Key therapy areas contributing to growth included cardiology, diabetology, respiratory, dermatology, gastrointestinal, anti-infectives, oncology, and nephrology.
International markets formulations revenue increased by 33% year-on-year to ₹10 billion, supported by broad-based demand across geographies. The North American business, including the United States and Canada, grew revenues by 21% year-on-year to ₹33.1 billion, driven by volume expansion and the scale-up of the US specialty pharmaceutical business.
US generics activities included filing 4 ANDAs, receiving 12 approvals, and launching 5 new products during the quarter. Notably, the company launched the first generic version of Riociguat tablets in October 2026. Specialty business growth was supported by the addition of Rolvedon through the acquisition of Assertio Holdings and traction in 505(b)(2) products.
The consumer wellness segment posted revenues of ₹11.2 billion, up 76% year-on-year. Domestic demand showed a steady urban recovery and improved rural sales, with skin and hair care plus food and nutrition portfolios delivering strong double-digit growth.
Operating profit remained strong with EBITDA at ₹18.9 billion. The company’s net debt to EBITDA ratio was 0.62 times as of September 30, 2026, and it continued to work with the USFDA to address observations from recent manufacturing facility inspections.
Highlights
- Consolidated revenue of ₹79.1 billion, a 29% increase year-on-year for Q2 FY27
- EBITDA margin maintained at 24% despite investments for Saroglitazar US launch
- India branded formulations grew 19% year-on-year, with a 20% increase in secondary sales
- International markets formulations revenue increased by 33% year-on-year to ₹10 billion
- North America business revenue of ₹33.1 billion, up 21% year-on-year, driven by generics and specialty portfolio expansion
- Launched 5 new US products including the first generic Riociguat tablets in October 2026 post-quarter end launch is notable future point but not for Q2 report itself; here for context only [excluded from highlights] to avoid inconsistency )
Key Data Snapshot
What happened
- Zydus Lifesciences reported consolidated revenues of ₹79.1 billion for Q2 FY27, a 29% increase year-on-year.
- EBITDA margin was maintained at 24% despite continued investments in the US Saroglitazar launch.
- Net profit for the quarter was ₹9.3 billion.
- Net debt to EBITDA ratio stood at 0.62 times as on September 30, 2026.
Financial performance
- India branded formulations business grew 19% year-on-year, outperforming the Indian pharmaceutical market with 20% growth in secondary sales.
- International formulations segment delivered ₹10 billion revenue, up 33% year-on-year.
- North America pharmaceutical business recorded ₹33.1 billion revenue, growing 21% year-on-year.
- Consumer wellness segment revenues increased 76% year-on-year to ₹11.2 billion.
Operational performance
- US generics division filed 4 ANDAs, received 12 approvals, and launched 5 new products during the quarter including the launch of generic Riociguat tablets in October 2026 post quarter.
- US specialty business expanded driven by Rolvedon addition and 505(b)(2) product portfolio.
- USFDA inspections of key manufacturing sites resulted in one observation at SEZ-II Ahmedabad and five at Moraiya; company is addressing them.
- A key transdermal patch approval was received on October 21, 2026.
Highlights
- Consolidated revenue of ₹79.1 billion, a 29% increase year-on-year for Q2 FY27
- EBITDA margin maintained at 24% despite investments for Saroglitazar US launch
- India branded formulations grew 19% year-on-year, with a 20% increase in secondary sales
- International markets formulations revenue increased by 33% year-on-year to ₹10 billion
- North America business revenue of ₹33.1 billion, up 21% year-on-year, driven by generics and specialty portfolio expansion
- Launched 5 new US products including the first generic Riociguat tablets in October 2026 post-quarter end launch is notable future point but not for Q2 report itself; here for context only [excluded from highlights] to avoid inconsistency )
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Source Information
More News on Earnings Call Transcript
View allLatest corporate announcements and market updates in Earnings Call Transcript.
Sunrakshakk Industries India Limited Posts INR 265.17 Crores Revenue with 130% PAT Increase in Q2 FY27
Sunrakshakk Industries India Limited reported its Q2 FY27 financial results with revenue of INR 265.17 crores and a profit after tax of INR 16 crores, reflecting year-on-year growth of 119.20% in revenue and 130.10% in PAT, supported by expansion in its FMCG, FMCG intermediates, and edible segments.
Read Full StoryReligare Enterprises Posts INR 4,717 Crores Income and INR 145 Crores Loss After Tax in H1 FY27, Resumes Lending and Strengthens Board
Religare Enterprises Limited has reported consolidated total income of INR 4,717 crores and a loss after tax of INR 145 crores for the half-year ending September 30, 2026, marking a 19% increase in income year-on-year. The company is transitioning from preparation to execution phase by strengthening its board with RBI-approved promoter and shareholder directors, resuming lending through Religare Finvest, and advancing growth in its core financial services and insurance businesses.
Read Full StoryBlack Box Limited Posts Record Q2 FY27 Revenue of INR 1,936 Crores and Expands Order Backlog to $1.04 Billion
Black Box Limited reported its highest-ever quarterly revenue of INR 1,936 crores for Q2 FY27, marking a 22% year-on-year increase, alongside an 88% year-on-year growth in its order backlog, which reached $1.04 billion as of September 2026. Data center order bookings crossed $250 million during H1 FY27, signaling strong momentum in hyperscale digital infrastructure projects.
Read Full Story